• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Precipio Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    4/9/25 6:03:45 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PRPO alert in real time by email
    false 0001043961 0001043961 2025-04-09 2025-04-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D. C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): April 9, 2025

     

    PRECIPIO, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   001-36439   91-1789357

    (State or other jurisdiction of

    incorporation)

      (Commission File Number)   (IRS Employer Identification No.)

     

    4 Science Park, New Haven, CT 06511

    (Address of principal executive offices) (Zip Code)

     

    (203) 787-7888

    (Registrant's telephone number, including area code)

      

     

     

    Not Applicable
    (Former name, former address and former fiscal year, if changed since last report date)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Ticker symbol(s) Name of each exchange on which
    registered
    Common Stock, $0.01 par value per share PRPO Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    (a)Resignation of Independent Registered Public Accounting Firm

     

    On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum LLP (“Marcum”). On April 9, 2025, Marcum informed Precipio Inc (the “Company”) that Marcum resigned as the Company’s independent registered public accounting firm as a result of such acquisition.

     

    The audit report of Marcum on the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principles.

     

    During the Company’s fiscal years ended December 31, 2024 and 2023, and the subsequent period through April 10, 2025, there were no (i) “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreement in their reports on the financial statements for such years, or (ii) “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K).

     

    In accordance with Item 304(a)(3) of Regulation S-K, the Company has provided Marcum with a copy of the foregoing disclosures and has requested that Marcum furnish the Company with a letter addressed to the Securities and Exchange Committee stating whether Marcum agrees with the statements made by the Company set forth above. A copy of Marcum’s letter, dated April 9, 2025, is filed as Exhibit 16.1 to this Current Report on Form 8-K.

     

    (b)Appointment of New Independent Registered Public Accounting Firm

     

    On April 9, 2025, the Audit Committee of the Company’s Board of Directors engaged CBIZ as the Company’s independent registered public accounting firm.

     

    During the fiscal years ended December 31, 2024 and 2023, and the subsequent period through [April 10], 2025 neither the Company, nor any party on behalf of the Company, consulted with CBIZ with respect to either (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided to the Company by CBIZ that CBIZ concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as defined in Item 304(a)(1)(v) of Regulation S-K).

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibits

     

     

     

     

    Exhibit No. Description
       
    16.1 Letter from Marcum LLP dated April 9, 2025
    104 Cover Page Interactive Data File (embedded within Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PRECIPIO, INC.
       
      By: /s/ Ilan Danieli
      Name: Ilan Danieli
      Title: Chief Executive Officer

     

    Date: April 9, 2025

     

     

    Get the next $PRPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

      NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

      3/21/22 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 89bio Announces Appointment of Kathy LaPorte to its Board of Directors

      SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

      11/3/21 8:00:00 AM ET
      $BOLT
      $ETNB
      $PRPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

      NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

      3/3/21 11:00:00 AM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precipio Announces Q1-2025 Shareholder Update Call

      NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio, Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10199645/ff1acc6c66 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions i

      5/1/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Announces Q4 and year-end 2024 Shareholder Update Call

      NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10197585/fea81a2627 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in su

      3/17/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

      NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports (unaudited) Adjusted EBITDA of $0.4M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other significant or non-operating (income) or expenses. Please see a detailed explanation at the bottom of this press release. Positive Cash flow. Precipio reports an (unaudited) increase of $0.3M in cash during Q4-2024. Of this improvement, $75,000 was due to directors' fees pai

      2/25/25 9:30:00 AM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    SEC Filings

    See more
    • Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Precipio, Inc. (0001043961) (Filer)

      5/6/25 4:00:22 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Precipio Inc.

      DEFA14A - Precipio, Inc. (0001043961) (Filer)

      4/30/25 2:00:41 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Precipio Inc.

      DEF 14A - Precipio, Inc. (0001043961) (Filer)

      4/30/25 2:00:26 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Precipio Inc.

      SC 13G - Precipio, Inc. (0001043961) (Subject)

      8/2/24 2:15:53 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Sabet Ahmed Zaki bought $474 worth of shares (79 units at $6.00), increasing direct ownership by 9% to 939 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      4/4/25 5:00:29 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: Director Sandberg Richard A sold $70,506 worth of shares (12,000 units at $5.88) and bought $91,430 worth of shares (15,000 units at $6.10), decreasing direct ownership by 73% to 4,525 units (SEC Form 4)

      4/A - Precipio, Inc. (0001043961) (Issuer)

      12/23/24 5:52:30 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Sandberg Richard A sold $74,400 worth of shares (12,000 units at $6.20) and bought $87,000 worth of shares (15,000 units at $5.80), decreasing direct ownership by 73% to 4,525 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      12/13/24 4:35:38 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Financials

    Live finance-specific insights

    See more
    • Precipio Announces Q1-2025 Shareholder Update Call

      NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio, Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10199645/ff1acc6c66 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions i

      5/1/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Announces Q4 and year-end 2024 Shareholder Update Call

      NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10197585/fea81a2627 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in su

      3/17/25 5:00:00 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

      NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports (unaudited) Adjusted EBITDA of $0.4M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other significant or non-operating (income) or expenses. Please see a detailed explanation at the bottom of this press release. Positive Cash flow. Precipio reports an (unaudited) increase of $0.3M in cash during Q4-2024. Of this improvement, $75,000 was due to directors' fees pai

      2/25/25 9:30:00 AM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PRPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sandberg Richard A was granted 2,946 shares, increasing direct ownership by 13% to 25,175 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      4/17/25 5:03:45 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Andrews Ronald Asbury was granted 1,785 shares, increasing direct ownership by 14% to 14,552 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      4/17/25 5:02:25 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Laporte Kathleen was granted 2,232 shares, increasing direct ownership by 22% to 12,303 units (SEC Form 4)

      4 - Precipio, Inc. (0001043961) (Issuer)

      4/17/25 5:01:38 PM ET
      $PRPO
      Biotechnology: Laboratory Analytical Instruments
      Industrials